Canada on omeprazole
This article was originally published in The Tan Sheet
Executive Summary
Long-term use of Nexium does not increase the risk of cardiovascular events, Health Canada announces Feb. 27. Additionally, the agency says it is unable to conclude definitively whether long-term use of Losec (omeprazole) increases cardiovascular risk, and will continue to evaluate it if more data emerge. The agency recommends patients taking either drug not change their medication unless directed by their doctor, "as ulcers and reflux can lead to other complications if left untreated." FDA conducted its own safety review of the products in August after study results raised questions about long-term use of the drugs and cardiovascular outcomes. However, the agency concluded the data did not indicate the presence of a true effect (1"The Tan Sheet" Dec. 17, 2007, In Brief)...
You may also be interested in...
PPIs heart safe
Use of AstraZeneca's proton-pump inhibitor Prilosec (omeprazole) or the follow-on Nexium (esomeprazole) does not increase the risk of cardiovascular events, according to a Dec. 10 statement by FDA. The administration assessed two small, long-term studies on Prilosec and Nexium reported earlier this year - both of which had raised a question as to whether long-term use of the drugs increased the number of heart attacks, heart failures and heart-related sudden death - as well as 14 comparative studies of Prilosec, four of which were placebo-controlled. FDA announced in August that it was conducting the greater review of safety data but based on preliminary data, health-care providers and patients should not change their prescribing or use practices, respectively (1"The Tan Sheet" Aug. 13, 2007, p. 3). Based on the now complete comprehensive, scientific review, FDA concluded that the frequency of cardiovascular events seen in the earlier analyses does not indicate the presence of a true effect...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.